Macular Degeneration is an eye disease affecting the macula (the centre of the light-sensitive retina at the back of the eye), causing loss of central vision. It's generally caused by abnormal blood vessels that leak fluid or blood into the macula. There are 2 types of age-related macular degeneration, such as dry and wet. There is no cure, but macular degeneration (AMD) treatment help slow the disease and keep people from having a severe vision loss. However, the treatment depends on the stage and type. Dry AMD tends to progress more slowly than the wet type, and there is not, as of yet, an approved treatment or cure. The dry type is more common, but it usually progresses slowly (over years). However, treatment depends on the type of AMD.
Market Dynamics:
Increasing prevalence of retinal disease, growing geriatric population, rise in demand for safe and effective treatment, and increasing number of clinical trials are major factors expected to propel growth of the global macular degeneration treatment market. For instance, according to the Centers for Disease Control and Prevention (CDC), age-related macular degeneration is a major cause of blindness worldwide and is the leading cause of vision loss and blindness for Americans aged 65 years and older, and the number of older Americans is projected to nearly double from 48 million to 88 million in 2050.
In September 2021, the United States Food and Drug Administration (FDA) approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye conditions, including neovascular age-related macular degeneration (nAMD), a leading cause of vision loss and blindness for Americans aged 65 years and older.
Key features of the study:
Detailed Segmentation:
Table of Contents:
*Browse 24 market data tables and 28 figures on "Global Macular Degeneration Treatment Market” - forecast to 2028
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients